Molecular Origin of Photovoltaic Performance in Donor-<i>block</i>-Acceptor All-Conjugated Block Copolymers by Kendall A. Smith (1477033)

“…All-conjugated block copolymers may be an effective route to self-assembled photovoltaic devices, but we lack basic information on the relationship between molecular characteristics and photovoltaic performance. Here, we synthesize a library of poly­(3-hexyl­thiophene) (P3HT) <i>block</i> poly­((9,9-dialkyl­fluorene)-2,7-diyl-<i>alt</i>-[4,7-bis­(alkyl­thiophen-5-yl)-2,1,3-benzo­thiadiazole]-2′,2″-diyl) (PFTBT) donor-<i>block</i>-acceptor all-conjugated block copolymers and carry out a comprehensive study of processing conditions, crystallinity, domain sizes, and side-chain structure on photovoltaic device performance. …”

DataSheet1_Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine.docx by Liang Zheng (206933)

Mean ± SEM FPKM values measured for differentially expressed genes. by Sarah W. Keenan (765990)

“…Only genes that changed by ≥ 2.0 fold or ≤ 0.5-fold were included. Several genes were abbreviated for simplicity: “PPBP,PF4,CXCL” includes Ppbp/Pf4/Cxcl1/Pf4v1/ Cxcl6/ Cxcl3/ Cxcl5/ Cxcl2/ Il8/ Cxcl10/ Cxc11; “CLK,PPIL3” includes Clk3/Ppil3/Clk1/Clk4). …”

The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus oxidation-reduction... by Seth H. Frisbie (7821866)

Serum 25(OH)VD3 levels in VD₃ sufficient and deficient mice. by Kavya Annu (11587215)

Proportion of VD₃ sufficient vs. deficient mice surviving from BCR-ABL ALL when treated with dexamethasone. by Kavya Annu (11587215)

DEX oral gavage PK raw data. by Kavya Annu (11587215)

Discontinuous DEX PK raw data from repeated study. by Kavya Annu (11587215)

Cartoon depicting dexamethasone and dasatinib metabolism and efflux transport in intestine and liver. by Kavya Annu (11587215)

Gene expression (qPCR) data from livers of C57BL/6 mice before and after DEX treatment. by Kavya Annu (11587215)

Raw data from survival study in VD₃ sufficient vs. deficient male mice from BCR-ABL ALL when treated with dexamethasone. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient hCYP3A4 12-week-old mice liver and kidney. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient C57BL/6 mice duodenum. by Kavya Annu (11587215)

Gene expression (qPCR) data from duodenums of C57BL/6 mice before and after DEX treatment. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient hCYP3A4 12-week-old mice duodenum. by Kavya Annu (11587215)

Kaplan-Meier curves for the effect of VD₃ sufficiency vs. deficiency on survival of mice from BCR-ABL Arf-/- leukemia. by Kavya Annu (11587215)

Cyp and transporter gene expression in liver and kidney of 12-week-old hCYP3A4 mice. by Kavya Annu (11587215)

Differences in plasma and gut dexamethasone concentrations following the oral discontinuous DEX regimen leads to tissue specific activation of GCR and PXR. by Kavya Annu (11587215)

Cartoon depicting hypothesis that dexamethasone-activated PXR can induce Cyp3a in VD₃ deficient mice, but not in VD₃ sufficient mice where 1,25(OH)<sub>2</sub... by Kavya Annu (11587215)

Dexamethasone plasma pharmacokinetics in male and female VD₃ sufficient and deficient mice, aged 14 weeks, after a single oral gavage of 2 mg/kg dexamethasone phosphate. by Kavya Annu (11587215)